Halozyme & ViroPharma to Develop Subcutaneous Cinryze

Under the agreement, Halozyme may receive as much as $83 million, with $9 million upfront and potential future milestone payments of $74 million based on clinical and regulatory targets, plus a 10% royalty on future sales.

Biotechnology company Halozyme Therapeutics and ViroPharma Incorporated announced Wednesday they have signed a worldwide exclusive licensing agreement for the use of rHuPH20 (recombinant human hyaluronidase) for the development of a subcutaneous formulation of Cinryze (C1 esterase inhibitor [human]).

Under the agreement, Halozyme may receive as much as $83 million, with $9 million upfront and potential future milestone payments of $74 million based on clinical and regulatory targets, plus a 10% royalty on future sales. ViroPharma will have exclusivity to C1 esterase inhibition and to the hereditary angioedema (HAE) indication, along with three additional orphan indications. ViroPharma will fund all development and commercialization expenses for the program.

Cinr